We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Use of Nasal Phenylephrine in Infants With Bronchiolitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00373802
First Posted: September 8, 2006
Last Update Posted: January 12, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Akron Children's Hospital
September 7, 2006
September 8, 2006
January 12, 2009
January 2005
June 2005   (Final data collection date for primary outcome measure)
Respiratory Distress Assessment Index at 5 minutes, 60 minutes, and 180 minutes.
Same as current
Complete list of historical versions of study NCT00373802 on ClinicalTrials.gov Archive Site
Respiratory rate, oxygen saturation and use of supplemental oxygen at 5, 60, and 180 minutes.
Same as current
Not Provided
Not Provided
 
The Use of Nasal Phenylephrine in Infants With Bronchiolitis
A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis
Drops of either saline or phenylephrine are placed in the nose of infants less than 12 months of age to determine if it helps them to breathe easier.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Bronchiolitis
Drug: Phenylephrine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
June 2005
June 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 4 weeks to 12 months; admitting diagnosis of bronchiolitis; admitted to hospital's bronchiolitis pathway, admitted during weekdays, need for nasal suctioning.

Exclusion Criteria:

  • Congenital heart disease, history of hypertension, previous wheezing, prior use of inhaled corticosteroids, gestational age at birth of <34 weeks.
Sexes Eligible for Study: All
up to 12 Months   (Child)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00373802
NASAL #9579
Not Provided
Not Provided
Not Provided
Nathan Kraynack, M.D., Akron Children's Hospital
Akron Children's Hospital
Not Provided
Principal Investigator: Rachel Konda-Sundheim, MD, MD Children's Hospital Medical Center of Akron
Akron Children's Hospital
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP